DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius ann

Fresenius SE & Co. KGaA / Key word(s): Quarter Results 30.07.2013 06:59 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fresenius announces H1/2013 record results, raises 2013 Group earnings guidance Group sales increased by 8% (9% in constant currency) to EUR9,987 million (H1/2012: EUR9,236 million). Organic sales growth was 5%. Acquisitions contributed a further 5%. Divestitures reduced sales growth by 1%. Group EBIT* increased by 1% (2% in constant currency) to EUR1,448 million (H1/2012: EUR1,440 million). The EBIT margin of 14.5% (H1/2012: 15.6%) was impacted by a margin decrease at Fresenius Medical Care as well as the first-time consolidation of Fenwal. However, Q2/2013 margin of 14.8% already showed a distinct improvement over Q1/2013 (14.2%). Group net income** increased by 11% (12% in constant currency) to EUR482 million (H1/2012: EUR434 million). Group net income attributable to shareholders of Fresenius SE & Co. KGaA including one-time integration costs for Fenwal was EUR462 million or EUR2.59 per share. Based on the Group's positive growth prospects for the second half of 2013, Fresenius raises its full-year earnings guidance. The company now expects net income*** to increase by 11% to 14% in constant currency. Previously, Fresenius expected net income growth of 7% to 12% in constant currency. The company fully confirms its sales guidance. Sales are expected to increase by 7% to 10% in constant currency. * 2013 excluding Fenwal integration costs (EUR27 million). 2012 excluding one-time costs related to the takeover offer to RHÃ?N-KLINIKUM AG shareholders (EUR7 million). ** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding Fenwal integration costs (EUR20 million); 2012 excluding a non-taxable investment gain (EUR34 million) as well as one-time costs related to the takeover offer to RHÃ?N-KLINIKUM AG shareholders (EUR26 million). *** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding Fenwal integration costs â??(~EURâ??50 million pre tax); 2012 excluding a non-taxable investment gain (EUR34 million) and other one-time costs at Fresenius Medical Care (EUR17 million) as well as one-time costs related to the takeover offer to RHÃ?N-KLINIKUM AG shareholders (EUR29 million). (Financial statements according to U.S. GAAP) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, Board of Management Bad Homburg v.d.H., July 30, 2013 End of note 30.07.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-StraÃ?e 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: ir-fre@fresenius.com Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard), München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------